Behçet Disease-associated Uveitis Successfully Treated with Golimumab. (19th December 2012)

• Record Type: Journal Article
• Authors: Mesquida, Marina; Victoria Hernández, María; Llorenç, Victor; Pelegrín, Laura; Espinosa, Gerard; Dick, Andrew D.; Adán, Alfredo
• Is Part Of: Ocular immunology and inflammation. Volume 21:Number 2(2013)
• Page Start: 160
• Page End: 162
• Publication Date: 2012-12-19
• Subjects: Behçet's Disease -- uveitis -- infliximab -- golimumab -- anti-TNF; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2012.741744
• Languages: English
• ISSNs: 0927-3948

Abstract

Abstract: Over the past decade, the off-label use of biologic agents such as TNF-α antagonists, including infliximab and adalimumab, has improved the treatment armamentarium for refractory immune-mediated uveitis, with particular success in Behçet disease-associated uveitis. Golimumab is a novel fully human anti-TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with very promising results. Herein, the authors present the use of GLM in a case of Behçet uveitis refractory to other TNF-α blockers. There are only two reports in the literature about the use of GLM in uveitis, describing four patients with JIA-associated uveitis and a case of idiopathic retinal vasculitis. To the authors' knowledge, this is the first report about the use of GLM in Behçet uveitis.